Semaglutide vs tirzepatide: cost and efficacy compared
One GLP-1 agonist, one dual agonist. The efficacy gap, the pricing gap, and a cost-per-result framework to decide which fits your goals and budget.
The efficacy comparison
Both are incretin-based injectables, but they differ mechanistically: semaglutide is a GLP-1 receptor agonist, while tirzepatide is a dual GIP/GLP-1 agonist. The direct head-to-head, SURMOUNT-5, found tirzepatide reached 20.2% mean weight loss versus 13.7% for semaglutide over 72 weeks. Semaglutide's own STEP 1 figure was ~14.9%. On average efficacy, tirzepatide leads — but semaglutide remains highly effective and better-studied over long horizons.
The cost comparison
Compounded semaglutide is frequently priced lower than compounded tirzepatide. In our July 2026 tracking, flat-rate compounded semaglutide runs about $145/month versus roughly $186/month for flat-rate compounded tirzepatide. On the brand side, both are expensive without insurance.
Cost per result
Dividing annual cost by trial-average efficacy is rough but useful. Flat-rate compounded semaglutide (~$1,740/yr ÷ 14.9%) is about $117 per percentage point; flat-rate compounded tirzepatide (~$2,232/yr ÷ 20.2%) is about $110. They're remarkably close — tirzepatide buys more absolute loss, semaglutide costs less per month. An illustrative comparison, not a clinical claim.
Tolerability, track record, and the practical tie-breakers
Efficacy and price get the headlines, but the decision often turns on quieter factors. Tolerability is broadly similar — both dominated by GI side effects that cluster during titration — though individual response varies enough that some people tolerate one markedly better. Because there's no way to predict this in advance, a program allowing a penalty-free switch has real option value. Track record is another tie-breaker: semaglutide has been in widespread use longer, with a deeper real-world literature including the SELECT cardiovascular trial. Availability and pricing consistency round it out: semaglutide programs are slightly more numerous and often a bit cheaper. The honest bottom line is that neither drug is universally better — they occupy different points on the efficacy-cost-evidence frontier. What we can say cleanly is the pricing: flat-rate compounded semaglutide is the lower monthly commitment. Suitability, dose, and switching are clinical decisions for a prescriber.
Frequently asked questions
Is tirzepatide or semaglutide more effective?
In SURMOUNT-5, tirzepatide produced greater average loss (20.2% vs 13.7% over 72 weeks). Semaglutide remains highly effective (~14.9% in STEP 1) with a longer track record. The best choice depends on individual priorities and suitability.
Is compounded semaglutide cheaper than tirzepatide?
Generally yes. In July 2026 tracking, flat-rate compounded semaglutide runs ~$145/month versus ~$186/month for flat-rate compounded tirzepatide. Both brand products are expensive without insurance.
Which has better cost-per-result?
They're close. Flat-rate compounded semaglutide is about $117 per percentage point of trial-average loss; tirzepatide about $110. Tirzepatide buys more absolute loss; semaglutide costs less per month.
Can I switch between them?
Switching is a clinical decision made with a prescriber based on response, tolerability, and goals. Both require their own titration schedules. Do not switch or adjust dosing without medical guidance.
Availability, switching, and the compounded-market picture
Beyond efficacy and price, the practical availability of each drug shapes real decisions, and here semaglutide has some quiet advantages worth naming. In the compounded telehealth market we track, semaglutide programs are slightly more numerous and geographically broader than tirzepatide programs, which can matter in states with thinner telehealth availability. Both drugs went through brand shortages that reshaped the compounded landscape, and both are now in a narrower regulatory environment where provider transparency matters more than the headline price. On switching: some patients start on one molecule and move to the other based on tolerability or plateau, and a program that permits this without penalty or a fresh signup fee has real value that is invisible at the initial price comparison. The compounded-market reality is that neither drug is a commodity; the pharmacy behind it, the clinical oversight wrapped around it, and the pricing structure determine value as much as the molecule choice. A cost-conscious reader is well served by treating the semaglutide-versus-tirzepatide question as the first of several decisions rather than the only one: which molecule, then which pricing model, then which provider on transparency and support. Getting the molecule right but the provider wrong can cost more, in money and outcome, than the efficacy gap between the two drugs. As always, the molecule and dose decision belongs with a prescriber who knows your history.
A simple decision framework
If you want a clean way to reason through the choice, order the questions by what they actually decide. Start with the clinical filter, which belongs to your prescriber: are there suitability factors, contraindications, or comorbidities that favor one molecule? That can settle the question before cost enters. If both are clinically reasonable, weigh how much the extra absolute weight loss is worth to you against the higher monthly cost of tirzepatide; SURMOUNT-5 suggests roughly six additional percentage points of average loss for about forty dollars more per month on flat-rate compounded pricing. If maximum efficacy is the priority and the budget allows, tirzepatide leads on the headline number. If predictable lower cost, a deeper long-term evidence base, and the cardiovascular data from SELECT matter more, semaglutide is the stronger pick. Then, whichever molecule wins, apply the same provider lens: flat-rate versus dose-tiered pricing, named and verifiable pharmacies, bundled clinical support, and fair switching and cancellation terms. This ordering keeps the decision honest, because it prevents a marketing-driven price from overriding a clinical judgment, and it prevents a molecule preference from excusing a weak provider. The molecule is the first decision, not the whole decision.
Availability, switching, and the compounded-market picture
Beyond efficacy and price, the practical availability of each drug shapes real decisions, and here semaglutide has some quiet advantages worth naming. In the compounded telehealth market we track, semaglutide programs are slightly more numerous and geographically broader than tirzepatide programs, which can matter in states with thinner telehealth availability. Both drugs went through brand shortages that reshaped the compounded landscape, and both are now in a narrower regulatory environment where provider transparency matters more than the headline price. On switching: some patients start on one molecule and move to the other based on tolerability or plateau, and a program that permits this without penalty or a fresh signup fee has real value that is invisible at the initial price comparison. The compounded-market reality is that neither drug is a commodity; the pharmacy behind it, the clinical oversight wrapped around it, and the pricing structure determine value as much as the molecule choice. A cost-conscious reader is well served by treating the semaglutide-versus-tirzepatide question as the first of several decisions rather than the only one: which molecule, then which pricing model, then which provider on transparency and support. Getting the molecule right but the provider wrong can cost more, in money and outcome, than the efficacy gap between the two drugs. As always, the molecule and dose decision belongs with a prescriber who knows your history.
References
- Aronne LJ, et al. Tirzepatide vs semaglutide (SURMOUNT-5). N Engl J Med. 2025.
- Wilding JPH, et al. STEP 1. N Engl J Med. 2021.
- RxCompareHub July 2026 dataset.
- FDA labeling for Wegovy, Ozempic, Zepbound, Mounjaro.
Clinical figures from published trials and FDA labeling; pricing from provider-advertised rates checked July 2026 and subject to change. Educational, not medical or financial advice.